(0.34%) 5 117.15 points
(0.33%) 38 365 points
(0.38%) 15 988 points
(-0.98%) $83.03
(5.56%) $2.03
(0.34%) $2 355.20
(0.49%) $27.67
(4.07%) $959.65
(-0.26%) $0.932
(-0.41%) $10.98
(-0.58%) $0.796
(1.69%) $93.43
Live Chart Being Loaded With Signals
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally...
Stats | |
---|---|
本日の出来高 | 1 780.00 |
平均出来高 | 201 477 |
時価総額 | 31.63M |
EPS | $0 ( 2024-04-01 ) |
次の収益日 | ( $-0.0500 ) 2024-05-15 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.170 |
ATR14 | $0.0290 (1.24%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-09-07 | Zukiwski Alexander A | Buy | 3 000 | Employee Stock Option (Right to Buy) |
2022-09-06 | Huang James | Buy | 33 300 | Common Stock |
2022-08-31 | Huang James | Buy | 400 | Common Stock |
2022-08-24 | Huang James | Buy | 39 527 | Common Stock |
2022-08-19 | Huang James | Buy | 40 000 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 95 transactions |
Buy: 27 815 562 | Sell: 9 916 643 |
CASI Pharmaceuticals Inc 相関
10 最も負の相関 | |
---|---|
ATHN | -0.923 |
SBNY | -0.91 |
CTAC | -0.9 |
CMLT | -0.9 |
KURI | -0.889 |
ITAC | -0.883 |
GLADL | -0.882 |
GCAC | -0.879 |
MCAE | -0.872 |
SRAC | -0.858 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
CASI Pharmaceuticals Inc 財務諸表
Annual | 2023 |
収益: | $33.88M |
総利益: | $18.98M (56.03 %) |
EPS: | $-2.02 |
FY | 2023 |
収益: | $33.88M |
総利益: | $18.98M (56.03 %) |
EPS: | $-2.02 |
FY | 2022 |
収益: | $43.11M |
総利益: | $27.28M (63.28 %) |
EPS: | $-2.89 |
FY | 2021 |
収益: | $30.17M |
総利益: | $17.61M (58.38 %) |
EPS: | $-0.332 |
Financial Reports:
No articles found.
CASI Pharmaceuticals Inc
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。